Literature DB >> 20428262

Role of the angiotensin II receptor blocker valsartan in heart failure.

R L Webb1, M de Gasparo.   

Abstract

Despite an enormous amount of research carried out in the past 10 to 20 years, the role of the renin-angiotensin system in the development of heart failure is still not very well understood. This review looks at preclinical data on the role of angiotensin II as a circulating and local hormone, and the effects of stimulation of the respective receptors in heart tissue. Recent large scale clinical trials have begun to furnish evidence of the effects of blocking the renin-angiotensin system in patients with heart failure using angiotensin-converting enzyme inhibitors or, more recently, angiotensin II receptor blockers that act directly at the receptor level, independent of pathways for angiotensin II generation. Results so far indicate that there are benefits from optimizing the blockade, but open questions remain, such as the role of endothelin and bradykinins, and the extent of crosstalk between the different systems.

Entities:  

Keywords:  Angiotensin II; Angiotensin II receptor blocker; Angiotensin-converting enzyme inhibitors; Apoptosis; Atherosclerosis; Chymase; Heart failure; Hypertension; Valsartan

Year:  2001        PMID: 20428262      PMCID: PMC2859003     

Source DB:  PubMed          Journal:  Exp Clin Cardiol        ISSN: 1205-6626


  86 in total

1.  Differential effects of angiotensin II receptor blockade on pressure-induced left ventricular hypertrophy and fibrosis in rats.

Authors:  H A Baba; T Iwai; M Bauer; M Irlbeck; K W Schmid; H G Zimmer
Journal:  J Mol Cell Cardiol       Date:  1999-02       Impact factor: 5.000

Review 2.  [Recent molecular and pharmacologic aspects of ACE inhibitors].

Authors:  H Köppel; B Eber; R Gasser; W Klein
Journal:  Wien Med Wochenschr       Date:  1995

3.  Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.

Authors:  J Biollaz; H R Brunner; I Gavras; B Waeber; H Gavras
Journal:  J Cardiovasc Pharmacol       Date:  1982 Nov-Dec       Impact factor: 3.105

4.  Healing human myocardial infarction associated with increased chymase immunoreactivity.

Authors:  M J Daemen; H Urata
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

5.  Angiotensin II induces apoptosis of human endothelial cells. Protective effect of nitric oxide.

Authors:  S Dimmeler; V Rippmann; U Weiland; J Haendeler; A M Zeiher
Journal:  Circ Res       Date:  1997-12       Impact factor: 17.367

6.  Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension.

Authors:  J Plum; B Bünten; R Németh; B Grabensee
Journal:  J Am Soc Nephrol       Date:  1998-12       Impact factor: 10.121

Review 7.  Blood pressure, systolic and diastolic, and cardiovascular risks. US population data.

Authors:  J Stamler; R Stamler; J D Neaton
Journal:  Arch Intern Med       Date:  1993-03-08

Review 8.  Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases.

Authors:  H Matsubara
Journal:  Circ Res       Date:  1998 Dec 14-28       Impact factor: 17.367

Review 9.  Mechanisms of angiotensin II formation in humans.

Authors:  H Urata; H Nishimura; D Ganten
Journal:  Eur Heart J       Date:  1995-12       Impact factor: 29.983

10.  Long-term treatment of spontaneously hypertensive rats with losartan and electrophysiological remodeling of cardiac myocytes.

Authors:  E Cerbai; A Crucitti; L Sartiani; P De Paoli; R Pino; M L Rodriguez; G Gensini; A Mugelli
Journal:  Cardiovasc Res       Date:  2000-01-14       Impact factor: 10.787

View more
  2 in total

1.  Angiotensin Type 1 Receptor Blockers in Heart Failure.

Authors:  Khuraijam Dhanachandra Singh; Sadashiva S Karnik
Journal:  Curr Drug Targets       Date:  2020       Impact factor: 3.465

2.  Effects of AT1 receptor antagonist therapy in patients with severe heart failure pretreated with angiotensin-converting enzyme inhibitors.

Authors:  Bernhard Gremmler; Matthias Kunert; Klaus Kisters; Heinrich Schleiting; Ludger J Ulbricht
Journal:  Exp Clin Cardiol       Date:  2002
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.